**4. Conclusions**

Our present examination of the chemical constituents of the soft coral *S. cherbonnieri* led to the discovery of new cembranoid compounds **1**–**7**. All compounds were found to possess anti-inflammatory activity by exhibiting inhibitory effects on the generation of superoxide anion and elastase release in fMLF/CB-induced primary human neutrophils, and cherbonolides G and H (**2** and **3**) were found to be the most active in the inhibition of elastase release and superoxide anion generation, respectively. As the marine environment is an important source of bioactive substances, and due to the high chemical diversity and specimen diversity of the *Sarcophyton* genus [27,28,34,35], it can be expected that new natural products and activities from soft corals of this genus can be continuously discovered in the future.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/1660-3397/18/11/573/s1. HR-ESI-MS, 1H-NMR, 13C-NMR, DEPT, HMQC, COSY, HMBC, and NOESY spectra of new compounds **1**–**7** are available online at http://www.mdpi.com/1660-3397/16/8/276/s1. Figure S1: HR-ESI-MS spectrum of **1**; Figure S2. 1H-NMR spectrum of **1** in C6D6; Figure S3. 13C-NMR spectrum of **1** in C6D6; Figure S4. HSQC spectrum of **1** in C6D6; Figure S5. 1H–1H COSY spectrum of **1** in C6D6; Figure S6. HMBC spectrum of **1** in C6D6; Figure S7. NOESY spectrum of **1** in C6D6; Figure S8. HR-ESI-MS spectrum of **2**; Figure S9. 1H-NMR spectrum of **2** in C6D6; Figure S10. 13C-NMR spectrum of **2** in C6D6; Figure S11. HSQC spectrum of **2** in C6D6; Figure S12. 1H–1H COSY spectrum of **2** in C6D6; Figure S13. HMBC spectrum of **2** in C6D6; Figure S14. NOESY spectrum of **2** in C6D6; Figure S15. HR-ESI-MS spectrum of **3**; Figure S16. 1H-NMR spectrum of **3** in C6D6; Figure S17. 13C-NMR spectrum of **3** in C6D6; Figure S18. HSQC spectrum of **3** in C6D6; Figure S19. 1H–1H COSY spectrum of **3** in C6D6; Figure S20. HMBC spectrum of **3** in C6D6; Figure S21. NOESY spectrum of **3** in C6D6; Figure S22. HR-ESI-MS spectrum of **4**; Figure S23. 1H-NMR spectrum of **4** in C6D6; Figure S24. 13C-NMR spectrum of **4** in C6D6; Figure S25. HSQC spectrum of **4** in C6D6; Figure S26. 1H-1HCOSY spectrum of **4** in C6D6; Figure S27. HMBC spectrum of **4** in C6D6; Figure S28. NOESY spectrum of **4** in C6D6; Figure S29. HR-ESI-MS spectrum of **5**; Figure S30. 1H-NMR spectrum of **5** in C6D6; Figure S31. 13C-NMR spectrum of **5** in C6D6; Figure S32. HSQC spectrum of **5** in C6D6; Figure S33. 1H–1H COSY spectrum of **5** in C6D6; Figure S34. HMBC spectrum of **5** in C6D6; Figure S35. NOESY spectrum of **5** in C6D6; Figure S36. HR-ESI-MS spectrum of **6**; Figure S37. 1H-NMR spectrum of **6** in CDCl3; Figure S38. 13C-NMR spectrum of **6** in CDCl3; Figure S39. HSQC spectrum of **6** in CDCl3; Figure S40. 1H–1H COSY spectrum of **6** in CDCl3; Figure S41. HMBC spectrum of **6** in CDCl3; Figure S42. NOESY spectrum of **6** in CDCl3; Figure S43. HR-ESI-MS spectrum of **7**; Figure S44. 1H-NMR spectrum of **7** in CDCl3; Figure S45. 13C-NMR spectrum of **7** in CDCl3; Figure S46. HSQC spectrum of **7** in CDCl3; Figure S47. 1H–1H COSY spectrum of **7** in CDCl3; Figure S48. HMBC spectrum of **7** in CDCl3; Figure S49. NOESY spectrum of **7** in CDCl3.

**Author Contributions:** Conceptualization, J.-H.S.; investigation, C.-C.P.; analysis, C.-C.P. and C.-Y.H.; writing—original draft, C.-Y.H., J.-H.S., and A.F.A.; writing—review and editing, J.-H.S.; anti-inflammatory assay, T.-L.H. All authors read and agreed to the published version of the manuscript.

**Funding:** Financial support of this work from the Ministry of Science and Technology of Taiwan (MOST 104-2113-M-110-006, 104-2320-B-110-001-MY2, and 107-2320-B-110-001-MY3) to J.-H.S. and further funding from the Deanship of Scientific Research at King Saud University through research group RG-1440-127.

**Conflicts of Interest:** The authors declare no conflict of interest.
